Setbacks hit two of the Swiss biotech’s clinical-stage darpin projects in a single day.
Rubraca has scored in an all-comers, first-line ovarian cancer maintenance setting, but Clovis has bigger problems.
Lynparza squares off against Zejula while Rubraca and Talzenna wait in the wings, but should first-line use be restricted by biomarkers?
The company’s androgen receptor degrader might have a pathway to approval, but the potential market looks small.
Praxis, Proqr and Nordic Nanovector are awaiting important data.
The first of 2021’s eight remaining oncology meetings kicks off next week. Here’s what to look out for.
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
177Lu-PSMA-617 shows impressive survival results in the Vision study, but early use will be key to fulfilling its potential.